OLLIE'S ORCHESTRA BECOMES INAUGURAL CHAMPION OF CHILDREN'S BRAIN TUMOR NETWORK
As the first recipient of the CBTN Champion designation, Ollie's Orchestra embodies a spirit of cooperation, championing the cause of pediatric brain tumor research. The nonprofit aims to leverage the partnership with CBTN to advance research and provide hope to families navigating pediatric brain tumors through free musical instruments, music classes, and other support resources.
"CBTN is the gold standard in children's cancer research. Together, we have the privilege to be part of solutions that will improve the lives of children, like Ollie, affected by cancer," says
The partnership between Ollie's Orchestra and CBTN signifies a shared vision of collaboration and compassion. Through its partnership with CBTN, Ollie's Orchestra aims to accelerate the development of effective treatments for childhood brain tumors while offering tangible support to children and families affected by this disease.
About Ollie's Orchestra
Founded by
About Children's Brain Tumor Network (CBTN)
Children's Brain Tumor Network (CBTN) is a collaborative research effort to accelerate treatments for children with brain tumors. CBTN's 34 international member institutions have enrolled over 5,000 study participants and gathered more than 69,000 biospecimen samples to create the world's most comprehensive repository of childhood brain tumors. CBTN's informatics and analytics platforms enable researchers to collaborate in real-time for children diagnosed with brain tumors.
Contact
Emily Reed, Children's Brain Tumor Network
[email protected]
View original content to download multimedia:https://www.prnewswire.com/news-releases/ollies-orchestra-becomes-inaugural-champion-of-childrens-brain-tumor-network-302153397.html
SOURCE Children’s Brain Tumor Network
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Swanson Vitamins Launches Swanson Vitamins Nexus Pro to Champion Registered Dietitians and Licensed Nutritionists at Every Stage of Their Careers
- Johnson & Johnson announces ERLEADA® (apalutamide) treatment before and after surgery reduces risk of recurrence or death by 62% versus surgery alone in high-risk prostate cancer
- DEEP Robotics Unveils Five Research Advances in Embodied AI
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!





Tweet
Share